Literature DB >> 6744775

Propafenone disposition kinetics in cardiac arrhythmia.

S Connolly, C Lebsack, R A Winkle, D C Harrison, R E Kates.   

Abstract

Propafenone disposition kinetics were studied after intravenous and oral doses in patients with ventricular arrhythmias. Plasma concentration-time data were fit to a two-compartment model for all but one patient, whose data required fitting to a three-compartment model. The model-independent calculated values of clearance, steady-state volume of distribution, and terminal t1/2 were 11.2 +/- 4.8 ml/min/kg, 3.6 +/- 2.1 l/kg, and 5.0 +/- 3.6 hr. After 5 days on oral propafenone, elimination t1/2 was 6.2 +/- 3.3 hr. The longer t1/2s and the estimates of steady-state bioavailability above 100% suggests that clearance decreases during chronic oral dosing. Considerable intersubject variability was noted in all disposition parameters.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6744775     DOI: 10.1038/clpt.1984.157

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Tissue distribution of propafenone in the rat after intravenous administration.

Authors:  J Fernández; L Lligoña; A Puigdemont; R Guitart; J L Riu; M Arboix
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

2.  Antiarrhythmic efficacy of propafenone: evaluation of effective plasma levels following single and multiple doses.

Authors:  L Frabetti; B Marchesini; A Capucci; C Cavallini; S Gubelli; E Ambrosioni; B Magnani
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Food increases the bioavailability of propafenone.

Authors:  J E Axelson; G L Chan; E B Kirsten; W D Mason; R C Lanman; C R Kerr
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

4.  Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration.

Authors:  P Giani; M Landolina; V Giudici; C Bianchini; G Ferrario; S Marchi; E Riva; R Latini
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Drug interaction between propafenone and metoprolol.

Authors:  F Wagner; D Kalusche; D Trenk; E Jähnchen; H Roskamm
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

Review 6.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

8.  Stereoselective steady state disposition and action of propafenone in Chinese subjects.

Authors:  G Li; P L Gong; J Qiu; F D Zeng; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 9.  New antiarrhythmic drugs in pediatric use: propafenone.

Authors:  T Paul; J Janousek
Journal:  Pediatr Cardiol       Date:  1994 Jul-Aug       Impact factor: 1.655

10.  Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.

Authors:  A Capucci; G Boriani; B Marchesini; E Strocchi; L Tomasi; M Balducelli; L Frabetti; E Ambrosioni; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.